Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study

Younes, Anas; Connors, Joseph M.; Park, Sophie; Fanale, Michelle A.; O’Meara, Megan M.; Hunder, Naomi; Huebner, Dirk; Ansell, Stephen M.

doi:10.1016/s1470-2045(13)70501-1

Cited by 252 publications

(178 citation statements)

References 21 publications

Supporting

Mentioning

167

Contrasting

Unclassified

Order By: Relevance

“…Additional FDG-PET/CT data using sequential BV followed by ICE chemotherapy before autologous stem cell transplantation have been reported 53 ; the PET 2 rate (5PS 1-3) using concurrent BV and ABVD or AVD chemotherapy for newly diagnosed HL was 96%. 54 The prognostic impact of FDG-PET/CT with incorporation of novel therapeutic agents should continue to be examined.…”

Section: Novel Therapeutic Agentsmentioning

confidence: 99%

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

Evens

Kostakoğlu

2014

Blood

View full text Add to dashboard Cite

Given the excellent survival rates for early-stage Hodgkin lymphoma (HL), the young age of many patients, and concerns regarding acute and late treatment-related toxicities, there is a desire to have a predictive tool that enables therapy to be tailored toward the individual patient. Early (or interim) 18F-fluorodeoxyglucose positron emission tomography with computerized tomography (FDG-PET/CT), as a test of tumor sensitivity to ongoing/planned therapy, has been shown to be prognostic for survival in HL. Based on results of interim FDG-PET/CT, therapy may be subsequently modified through minimization or via intensification for low- and high-risk patient populations, respectively (ie, response-adapted therapy). Important data have been generated to standardize the interpretability and reproducibility of interim FDG-PET/CT (eg, the Deauville 5-point system), and observational and noncontrolled prospective studies have produced evidence supporting the hypothesis that response-adapted therapy may potentially serve as a predictive tool. Furthermore, results from noninferiority phase 3 clinical trials randomizing early-stage HL patients with negative interim FDG-PET/CT to combined modality therapy versus chemotherapy alone have been reported. The current collective findings from these randomized early-stage HL studies have shown that acute relapse rates are lower with combined modality therapy, even in patients with negative interim FDG-PET/CT. Additional randomized response-adapted studies are ongoing and novel FDG-PET/CT applications involving quantitative techniques and innovative imaging modalities are being investigated to identify more robust imaging biomarkers. Treatment of early-stage HL remains a clinical management choice for physicians and patients to make with consideration of acute and long-term outcomes.

show abstract

Section: Novel Therapeutic Agentsmentioning

confidence: 99%

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

Evens

Kostakoğlu

2014

Blood

View full text Add to dashboard Cite

show abstract

“…54 The prognostic impact of FDG-PET/CT with incorporation of novel therapeutic agents should continue to be examined.…”

Section: Novel Therapeutic Agentsmentioning

confidence: 99%

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

Evens

Kostakoğlu

2014

Hematology

View full text Add to dashboard Cite

show abstract

“…Regarding Brentuximab as front-line therapy, a phase I study of 51 patients with advanced HL 15 compared conventional ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy combined with 1.2mg/kg BV (ABVD-Adcetris or 'ABVD-A'), against the same regimen without bleomycin (AVD-A). ABVD-A had an unacceptable rate of pulmonary toxicity (including two patient deaths), whereas no pulmonary side effects were seen with AVD-A, i.e.…”

Section: Accepted Articlementioning

confidence: 99%

Recent treatment advances in Hodgkin lymphoma: a concise review

Arulogun

Hertzberg

Gandhi

2016

Internal Medicine Journal

View full text Add to dashboard Cite

The majority of patients with Hodgkin Lymphoma enjoy durable remissions following front-line treatment. This typically involves combination chemotherapy with or without radiotherapy. A significant minority of patients experience relapsed/refractory disease, of whom only approximately half can be 'salvaged' with conventional second-line treatments. Until recently, for those patients either failing or who are not fit for salvage, there have been few curative alternatives. Furthermore, there is a significant risk of delayed treatment complications to conventional therapies, including secondary malignancies and cardiac disease. However, novel targeted therapies are producing excellent results in clinical trials. They provide additional treatment options for those with relapsing/refractory disease; they may also have potential in front-line therapy. The anti-CD30 antibody brentuximab vedotin has been tested as monotherapy and in combination in a variety of clinical settings, including in relapsed/refractory patients and as consolidative therapy following standard second-line therapy. Nivolumab and Pembrolizumab, currently used in other malignancies that are also known to utilise the programmed death pathway for survival, have shown outstanding results when used as single agents in heavily pre-treated (including brentuximab vedotin refractory) patients. Individualising and adapting a patient's treatment course, whether augmenting or rationalising therapy, based on an interim PET/CT response is an important strategy currently under exploration to minimise toxicity while maximising response. Further work is needed to explore clinical and biological factors associated with improved outcomes. Knowledge of these factors combined with the movement of novel therapies into the front-line setting will enable individualised therapy to enhance clinical responses and minimize toxicities.

show abstract

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study

Cited by 252 publications

References 21 publications

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

Recent treatment advances in Hodgkin lymphoma: a concise review

Contact Info

Product

Resources

About